Goldsboro Daily News: Daily Updates Reflect News And Community Events In Wayne County's Free News Source.
The Goldsboro News-Argus is a daily newspaper published in Goldsboro, North Carolina, that serves the residents of Wayne County. The Goldsboro News-Argus was founded in 1885 as the Daily Argus, and in 1929 it merged with the Goldsboro News to become the Goldsboro News-Argus.
Author:Paolo ReynaReviewer:Hajra ShannonSep 24, 202134K Shares549.1K Views
The Goldsboro News-Argus is a daily newspaper published in Goldsboro, North Carolina, that serves the residents of Wayne County. The Goldsboro News-Argus was founded in 1885 as the Daily Argus, and in 1929 it merged with the Goldsboro News to become the Goldsboro News-Argus.
The firm also produces the Community Yellow Pages of Eastern North Carolina and the Community Phone Book of Wayne County, as well as a telephone directory. The Wright Times, written by and for the residents of the Seymour Johnson Air Force Base, and the Roanoke Beacon, a smaller newspaper serving Plymouth, North Carolina, which was acquired by the News-Argus in January 2006, are both published by the Wayne Publishing Company.
The newspaper is linked with the following quote: "This Argus keeps an everlasting watch over the liberties of the people. Its hundred eyes cannot be lulled to sleep by o'Malia's son's soothing melodies."
The Argus became an afternoon issue in 1922, and another daily, The Goldsboro News, was established the same year. Roland Beasley, John Beasley, Matt H. Allen, R.E. Powell, W.W. Minton, and John D. Langston founded The News, a morning newspaper.
In 1929, a man called Talbot Patrick bought a majority stake in both publications, and they were combined. The Goldsboro News-Argus concluded talks to relocate to a new site in the winter of 1933, a brick structure previously owned by the Goldsboro Grocery Company. The new structure was placed in service in May 1934, and it was subsequently renovated and expanded in 1964. Patrick stayed on as publisher of the publication until October 1, 1953.
After outgrowing its old facility and its capability for publishing, the newspaper commissioned a new structure from architect Conrad Wessell, which was completed in 1970. The Goldsboro News-Argus was purchased from Patrick and other shareholders by Wayne Printing Co., Inc. of North Carolina in October 1953. Hal H. Tanner Sr. became the company's new publisher and president and was followed in 1984 by his son, Hal Tanner Jr., and grandson, Hal H. Tanner III.
Vitamin D Can Be Cheap Treatments For Covid-19
The reproduction and growth of COVID-19 may be inhibited by active forms of vitamin D, according to a recent study from the University of Alabama in Birmingham. The results also indicate that lumisterol, which is generated in the body via a chemical process involving light, helps to inhibit COVID-19.
Two particular enzymes (RdRP and Mrpo) essential for the SARS-CoV-2 life cycle were blocked by vitamin D and lumisterol metabolites. In September 2020, Anthony Fauci, MD, head of the National Institute of Allergy and Infectious Diseases, proposed that vitamin D may aid in the battle against COVID-19. He also calculated that 40% of the population in the United States is vitamin D deficient.
The researchers were able to demonstrate that new and physiologically relevant vitamin D and lumisterol derivatives operate on numerous sites, suggesting that they may be effective against both original and mutant SARS-CoV-2 strains. Another advantage of vitamin D is its cheap cost and accessibility. Vitamin D is converted into different active forms by enzymes known as cytochrome oxidases, or CYP enzymes after it is ingested.
The results may help explain why low vitamin D levels seem to increase COVID-19 infection and bad outcomes in certain people, according to the researchers. This is consistent with previous research that has linked vitamin D insufficiency to poor illness outcomes. More research and clinical trials will be conducted to determine the effectiveness of vitamin D and lumisterol as COVID-19 antiviral therapeutics in animals and people.
Vitamin D and COVID 19: The Evidence for Prevention and Treatment of Coronavirus (SARS CoV 2)
Infected With Covid: This Simple Treatment Could Help Keep You Out Of The Hospital
If you acquire COVID-19, there's a simple therapy that may help you stay out of the hospital: monoclonal antibodies.
The therapy, which helps accelerate your body's immunological response to the infection, is available at most hospitals. It takes around an hour and a half to deliver and is administered through IV infusion.
One Blood Type May Protect Against Covid Infection
Coronavirus infection is less likely in people with this blood type. Human ABO blood types may influence susceptibility to COVID-19 and the severity of the disease.
According to studies, persons with blood types A and AB are more likely to acquire severe COVID, while those with blood type O are less likely to become infected. People of blood type O seem to be less susceptible to the virus, thus they have the lowest chance of severe illness, hospitalization, and death. While the coronavirus epidemic continues, scientists are working to identify risk factors and develop strategies to reduce them.
COVID and the severity of the disease in infected individuals seem to be linked, and blood type appears to be a possible risk factor. A Danish researcher compared data from almost half a million persons who had been tested for COVID with data from over two million people who had not been tested.
The researchers discovered that individuals with blood types A, AB, and B were more likely to test positive for coronavirus, whereas those with blood type O were less likely. Blood type O seems to have the potential to protect its owner against coronavirus infection, according to scientific data. Although blood type O lacks antigens, it does contain anti-A and anti-B antibodies, which may destroy the virus when it enters human cells.
Do People with Certain Blood Types Have Worse Covid-19 Symptoms?
You, Will, Have "Superhuman Immunity" To Covid-19 If You Were Infected And Then Injected MRNA Vaccine
It's been dubbed "superhuman immunity" or "bulletproof" by some scientists. Shane Crotty, an immunologist, favors the term "hybrid immunity." In a June editorial in Science, Crotty stated, "Overall, hybrid immunity against SARS-CoV-2 seems to be remarkably effective." Whatever you name it, this kind of immunity is welcome news in the midst of what seems like an unending stream of terrible news about COVID-19.
A number of research published in the last several months have shown that certain individuals have a very strong immune response to SARS-CoV-2, the coronavirus that causes COVID-19. Their bodies generate a lot of antibodies, but they also manufacture antibodies that are highly adaptable, meaning they can fight against current coronavirus variations while still being effective against variants that may arise in the future. "One might fairly anticipate that most if not all of the SARS-CoV-2 variants that we are going to encounter in the near future would be very well protected," says Paul Bieniasz, a virologist at Rockefeller University who helped conduct many of the experiments.
There’s Growing Concern Vaccinated People May Be More Vulnerable To Covid-19 Than Previously Thought
While vaccination clearly protects against the coronavirus, experts are becoming worried that vaccinated individuals may be more vulnerable to severe disease than previously believed.
According to a Bloomberg article, this increasing worry comes amid a scarcity of scientific research with definitive answers, leaving public officials and business leaders with only "fragmented" data on which to base their decisions.
As a consequence, mask requirements are being extended and office reopenings are being postponed, according to the study, while other authorities choose to preserve the status quo, claiming a "lack of clarity" to explain their choices.
Bloomberg stated, "Anecdotes tell us what statistics can't: Vaccinated individuals seem to be acquiring the coronavirus at a shockingly high rate." The frequency with which this occurs, as well as the probability of those individuals transmitting the virus to others, are unknown.
Vaccinated individuals are less likely to need hospital care for COVID-19 and are less likely to need ventilators, according to Bloomberg. Those who have received the COVID-19 vaccination also have a lower risk of dying. However, approximately 30% of people have not yet been vaccinated. In addition, physicians are keeping an eye on illnesses among vaccine recipients.
COVID-19 Vaccine Breakthrough Infections
This Depression Drug Can Save Covid-19 Patients, Study Finds
According to a recent study from McMaster University, a cheap oral antidepressant may save COVID-19 patients' lives and reduce hospital stays by up to 30%. Between January 20 and August 6, they gave fluvoxamine to 738 randomly chosen Brazilian COVID-19 patients, while another 733 were given a placebo.
Every patient who receives fluvoxamine throughout the study is followed for 28 days to see how they are doing and if they still need hospital care. When comparing individuals who received fluvoxamine to those who did not, the researchers discovered a 30% decrease in incidents. The fluvoxamine study is part of the broader TOGETHER Trial, which began in May 2020 with the goal of evaluating possible COVID-19 therapies in a community environment.
Scientists in the TOGETHER Trial tried eight medicines, including hydroxychloroquine, metformin, kaletra, and ivermectin, but only fluvoxamine had a favorable impact on COVID-19.
According to the researchers, fluvoxamine is the only medication that may prevent COVID-19 from becoming a life-threatening disease if given early. It has the potential to be one of the most efficient weapons against the virus, and its efficacy is one of the most significant discoveries we've discovered since the outbreak started. Furthermore, this low-cost, readily available tablet is a huge benefit to public health in Canada and across the world, enabling hospitals to avoid costly and often dangerous procedures.
Fluvoxamine, which costs approximately $4 per 10-day course, may be a game-changer for impoverished nations with low immunization rates and limited access to more sophisticated COVID-19 treatments, according to the researchers.
Can we use a depression treatment drug to treat COVID? What do we know so far?
Jump to
Vitamin D Can Be Cheap Treatments For Covid-19
Infected With Covid: This Simple Treatment Could Help Keep You Out Of The Hospital
One Blood Type May Protect Against Covid Infection
You, Will, Have "Superhuman Immunity" To Covid-19 If You Were Infected And Then Injected MRNA Vaccine
There’s Growing Concern Vaccinated People May Be More Vulnerable To Covid-19 Than Previously Thought
This Depression Drug Can Save Covid-19 Patients, Study Finds
Paolo Reyna
Author
Paolo Reyna is a writer and storyteller with a wide range of interests. He graduated from New York University with a Bachelor of Arts in Journalism and Media Studies.
Paolo enjoys writing about celebrity culture, gaming, visual arts, and events. He has a keen eye for trends in popular culture and an enthusiasm for exploring new ideas. Paolo's writing aims to inform and entertain while providing fresh perspectives on the topics that interest him most.
In his free time, he loves to travel, watch films, read books, and socialize with friends.
Hajra Shannon
Reviewer
Hajra Shannona is a highly experienced journalist with over 9 years of expertise in news writing, investigative reporting, and political analysis.
She holds a Bachelor's degree in Journalism from Columbia University and has contributed to reputable publications focusing on global affairs, human rights, and environmental sustainability.
Hajra's authoritative voice and trustworthy reporting reflect her commitment to delivering insightful news content.
Beyond journalism, she enjoys exploring new cultures through travel and pursuing outdoor photography
Latest Articles
Popular Articles